cadila report weak quarter ebitda miss pre
cost level stay elev cadila us perform in-
line qoq increas driven tamiflu ex-u perform
weak throughout region cut ep factor
weak margin ex-u weak sale cut tp rs
cadila guid core margin ex lialda improv
bp us sale increas yoy view us
sale guidanc impli cadila factor competit
lialda otherwis would difficult grow us sale
authoris gener asacol transderm launch
delay cadila expect launch alreadi
approv model sale declin us
work capit cadila expand sharpli day
day proport sale us increas
channel consolid impact higher chargeback
result mute debt reduct despit strong lialda sale
lialda cadila continu maintain volum share post
teva entri though price come-off like
estimate pot chg tp
 chang prev ep
note cadila healthcar diversifi indian pharmaceut compani focus develop
manufactur sell distribut product
click detail financi
weak quarter ebitda miss
level stay elev cadila reason cadila
miss oper profit last three quarter
us sale in-lin sequenti increas help higher
tamiflu sale howev sale perform region
quit weak cost trend personnel cost expens
continu stay high result ebitda miss estim
due low ebitda pre miss
manag confer call mention one-off cost
quarter low therefor larg current cost base
sustain therefor cut estim factor
higher cost delay toprol launch transderm launch
target price cut rs factor earn
figur weak sale outsid us us boost tamiflu
guidanc improv core margin bp grow
us sale yoy
cadila guid improv core margin ex one-off like lialda
bp cadila also expect overal us sale increas
view guidanc impli cadila factor
entri lialda year otherwis would difficult cadila
grow us consid lot competit
enter tamiflu higher-margin transderm launch also
delay cadila guid launch product us
alreadi approv product model
declin us sale entri assum lialda
also expect anoth authoris gener asacol hd
cadila get launch product
lialda teva entri impact price cadila share
cadila continu maintain market share lialda even
teva entri mention price come
post teva entri model price eros lialda
wc cycl expand sharpli
work capit cycl cadila increas sharpli last
two year proport sale us increas
impact channel consolid higher chargeback higher
wc impact net debt reduct despit strong lialda sale
figur sharp increas wc cycl
us sale
figur ebitda miss despit low high cost continu
seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid
report singl factor make invest decis
compani mention price
anubhav aggarw certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
price rate histori cadila healthcar cadi bo
signifi initi assumpt coverag
price rate histori teva pharmaceut teva
signifi initi assumpt coverag
decemb analyst stock rate defin follow
outperform stock total return expect outperform relev benchmark next month
neutral stock total return expect line relev benchmark next month
under-perform stock total return expect under-perform relev benchmark next month
relev benchmark region decemb japanes rate base stock total return rel analyst coverag univers
consist compani cover analyst within relev sector outperform repres attract neutral less attract
underperform least attract invest opportun octob canadian well european ra ting base stock total return
rel analyst coverag univers consist compani cover analyst within relev sector outperform repres
attract neutral less attract underperf orm least attract invest opportun latin american asia stock exclud japan
australia rate base stock total return rel averag total return relev countri regio nal benchmark india bse sensex index
prior octob canadian rate base stock absolut total return potenti curren share price rel
attract stock total return potenti within analyst coverag univers australian new zealand stock expect total return calcul
includ roll dividend yield outperform rate assign greater equal under-perform wh ere less
equal neutral may assign overlap rate rang allow analyst assign rate put
context associ risk prior may rang outperform underp form rate overlap neutral threshold
oper juli
restrict certain circumst credit suiss polici and/or applic law regul preclud certain type commun
includ invest recommend cours credit suiss engag invest bank transact certain
rate nr credit suiss equiti research invest rate view stock secur relat compani
time
cover nc credit suiss equiti research provid on-going coverag compani offer invest rate invest view
equiti secur compani relat product
volatil indic stock defin volatil stock price move month least past
month analyst expect signific volatil go forward
analyst sector weight distinct analyst stock rate base analyst expect fundament and/or valuat
sector rel group histor fundament and/or valuat
overweight analyst expect sector fundament and/or valuat favor next month
market weight analyst expect sector fundament and/or valuat neutral next month
underweight analyst expect sector fundament and/or valuat cautiou next month
analyst coverag sector consist compani cover analyst within relev sector analyst may cov er multipl sector
credit suiss distribut stock rate bank client
bank client
purpos nyse finra rate distribut disclosur requir stock rate outperform neutral nd under-perform close correspond
